Volume 1 Issue 3
Dec.  2022
Turn off MathJax
Article Contents
Article Navigation >  Clinical Cancer Bulletin  > 2022  >  1(3): 144-148
Ha WU, Guobing LIU, Yibo HE, Zhe ZHENG, Hongcheng SHI. Comparison of Capillary and Venous Glucose Concentrations: A Real-world Study in Patients Undergoing Fluorodeoxyglucose–positron Emission Tomography[J]. Clinical Cancer Bulletin, 2022, 1(3): 144-148. doi: 10.11910/j.issn.2791-3937.2022.20220019
Citation: Ha WU, Guobing LIU, Yibo HE, Zhe ZHENG, Hongcheng SHI. Comparison of Capillary and Venous Glucose Concentrations: A Real-world Study in Patients Undergoing Fluorodeoxyglucose–positron Emission Tomography[J]. Clinical Cancer Bulletin, 2022, 1(3): 144-148. doi: 10.11910/j.issn.2791-3937.2022.20220019
shu

Comparison of Capillary and Venous Glucose Concentrations: A Real-world Study in Patients Undergoing Fluorodeoxyglucose–positron Emission Tomography

doi: 10.11910/j.issn.2791-3937.2022.20220019
  • 1.

    Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China

  • 2.

    Institute of Nuclear Medicine, Fudan University, Shanghai 200032, China

  • 3.

    Shanghai Institute of Medical Imaging, Shanghai 200032, China

  • 4.

    Cancer Prevention and Treatment Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China

  • 5.

    Department of Nuclear Medicine, Children’s Hospital, Fudan University, Shanghai 201102, China

More Information
  • Corresponding author: Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China. Email address: shi.hongcheng@zs-hospital.sh.cn
  • Received Date: 16 Nov 2022
  • Accepted Date: 27 Feb 2023
    • Available Online: 13 Mar 2023
  • Publish Date: 25 Dec 2022
    Abstract
  •   Objective  Fasting capillary blood glucose (CBG) must be measured before fluorodeoxyglucose–positron emission tomography (FDG–PET) imaging. In this study, we aimed to investigate whether a recently measured fasting venous blood glucose (VBG) concentration could be substituted for CBG.   Methods  This retrospective study included 520 of 1,378 patients who had undergone FDG–PET at our institution in June 2022. None of the study patients had a history of diabetes mellitus. Each study patient’s CBG was measured immediately before FDG administration, whereas the VBG (VBG < 7.8 mmol/L) was measured within one week before and after PET imaging. We used Bland−Altman plots to compare the two blood glucose concentrations.   Results  The 520 participants (315 male, 205 female; ages 13–87 years) accounted for 37.7% (520/1378) of all patients. The median CBG and VBG were 5.7 mmol/L (interquartile range, 5.2–6.2 mmol/L) and 5.1 mmol/L (interquartile range, 4.8–5.8 mmol/L), respectively. There was a moderate positive correlation between CBG and VBG (r=0.4370, 95% CI: 0.3625–0.5059, P<0.0001). Bland–Altman plots revealed that only 5.8% (30/520) of the dots exceeded the 95% limits of agreement and these were all within acceptable limits, indicating that the bias was not clinically significant.   Conclusion  When performing FDG–PET on patients without diabetes, a VBG of < 7.8 mmol/L within the previous week may be an acceptable alternative to CBG.

     

    • FullText(HTML)
  • loading

    • All authors declare that they have no conflicts of interest.

    References(20)
  • [1]
    Rocha A, Bellaver B, Souza DG, Schu G, Fontana IC, Venturin GT, et al. Clozapine induces astrocyte-dependent FDG-PET hypometabolism. Eur J Nucl Med Mol Imaging, 2022, 49: 2251–64. doi: 10.1007/s00259-022-05682-3
    [2]
    Rinkin C, Fosse P, Malaise O, Chapelier N, Horrion J, Seidel L, et al. Dissociation between 2-[18F] fluoro-2-deoxy-D-glucose positron emission computed tomography, ultrasound and clinical assessments in patients with non-severe rheumatoid arthritis, including remission. BMC Rheumatol, 2021, 5: 31. doi: 10.1186/s41927-021-00196-1
    [3]
    Paulus A, Drude N, van Marken Lichtenbelt W, Mottaghy FM, Bauwens M. Brown adipose tissue uptake of triglyceride-rich lipoprotein-derived fatty acids in diabetic or obese mice under different temperature conditions. EJNMMI Res, 2020, 10: 127. doi: 10.1186/s13550-020-00701-6
    [4]
    Eskian M, Alavi A, Khorasanizadeh M, Viglianti BL, Jacobsson H, Barwick TD, et al. Effect of blood glucose level on standardized uptake value (SUV) in 18F-FDG PET-scan: a systematic review and meta-analysis of 20, 807 individual SUV measurements. Eur J Nucl Med Mol Imaging, 2019, 46: 224–37. doi: 10.1007/s00259-018-4194-x
    [5]
    Finessi M, Bisi G, Deandreis D. Hyperglycemia and 18F-FDG PET/CT, issues and problem solving: a literature review. Acta Diabetol, 2020, 57: 253–62. doi: 10.1007/s00592-019-01385-8
    [6]
    Sarikaya I, Sarikaya A, Sharma P. Assessing the Effect of Various Blood Glucose Levels on 18F-FDG Activity in the Brain, Liver, and Blood Pool. J Nucl Med Technol, 2019, 47: 313–18. doi: 10.2967/jnmt.119.226969
    [7]
    Viglianti BL, Wong KK, Wimer SM, Parameswaran A, Nan B, Ky C, et al. Effect of hyperglycemia on brain and liver 18F-FDG standardized uptake value (FDG SUV) measured by quantitative positron emission tomography (PET) imaging. Biomed Pharmacother, 2017, 88: 1038–45. doi: 10.1016/j.biopha.2017.01.166
    [8]
    Kubota K, Watanabe H, Murata Y, Yukihiro M, Ito K, Morooka M, et al. Effects of blood glucose level on FDG uptake by liver: a FDG-PET/CT study. Nucl Med Biol, 2011, 38: 347–51. doi: 10.1016/j.nucmedbio.2010.09.004
    [9]
    Oh DY, Kim JW, Koh SJ, Kim M, Park JH, Cho SY, et al. Does diabetes mellitus influence standardized uptake values of fluorodeoxyglucose positron emission tomography in colorectal cancer? Intest Res, 2014, 12: 146-52.
    [10]
    Rosica D, Cheng SC, Hudson M, Sakellis C, Van den Abbeele AD, Kim CK, et al. Effects of hyperglycemia on fluorine-18-fluorodeoxyglucose biodistribution in a large oncology clinical practice. Nucl Med Commun, 2018, 39: 417–22. doi: 10.1097/MNM.0000000000000829
    [11]
    Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. ; European Association of Nuclear Medicine (EANM). FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging, 2015, 42: 328–54. doi: 10.1007/s00259-014-2961-x
    [12]
    Kang Y, Lu JM, Sun JF, Li CL, Wang XL, Zhang XQ, et al. Characteristics of glycemic excursion in different subtypes of impaired glucose intolerance. Zhonghua Yi Xue Za Zhi, 2009, 89: 669–72.Chinese.
    [13]
    Wang C, Lv L, Yang Y, Chen D, Liu G, Chen L, et al. Glucose fluctuations in subjects with normal glucose tolerance, impaired glucose regulation and newly diagnosed type 2 diabetes mellitus. Clin Endocrinol (Oxf), 2012, 76: 810–5. doi: 10.1111/j.1365-2265.2011.04205.x
    [14]
    Kaiser A, Davenport MS, Frey KA, Greenspan B, Brown RKJ. Management of Diabetes Mellitus Before 18F-Fluorodeoxyglucose PET/CT: A Nationwide Patient-Centered Assessment of Approaches to Examination Preparation. J Am Coll Radiol, 2019, 16: 804–09. doi: 10.1016/j.jacr.2018.09.006
    [15]
    Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med, 2006, 47: 885–95.
    [16]
    Dimitriadis GD, Maratou E, Kountouri A, Board M, Lambadiari V. Regulation of Postabsorptive and Postprandial Glucose Metabolism by Insulin-Dependent and Insulin-Independent Mechanisms: An Integrative Approach. Nutrients, 2021, 13: 159. doi: 10.3390/nu13010159
    [17]
    Banks KP, Bradley YC, Parisi MT, et al. ACR-SPR practice parameter for performing FDG-PET/CT in oncology. Available at: https://www.acr.org/-/media/ACR/Files/Practice-Parameters/FDG-PET-CT.pdf. Accessed July 15, 2018.
    [18]
    American Diabetes Association Professional Practice Committee. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care, 2022, 45: S17–S38. doi: 10.2337/dc22-S002
    [19]
    Paquet N, Albert A, Foidart J, Hustinx R. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. J Nucl Med, 2004, 45: 784–8.
    [20]
    Hadi M, Bacharach SL, Whatley M, Libutti SK, Straus SE, Rao VK, et al. Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the "glucose-corrected" SUV. Nucl Med Biol, 2008, 35: 441–5. doi: 10.1016/j.nucmedbio.2008.02.007
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article Views(255) PDF Downloads(19) Cited by()
    Proportional views
    Related

    Contacts

    Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return